Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

[1]  M. Dimopoulos,et al.  Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. , 2020, JAMA oncology.

[2]  N. Geller,et al.  Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). , 2020 .

[3]  B. Barlogie,et al.  Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) , 2020, Blood Cancer Journal.

[4]  U. Mellqvist,et al.  Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud , 2020, The Lancet. Haematology.

[5]  C. Hofmeister,et al.  Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Voorhees,et al.  Extramedullary multiple myeloma , 2019, Leukemia.

[7]  Nisha S Joseph,et al.  Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone , 2019, Blood Cancer Journal.

[8]  P. Sonneveld,et al.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.

[9]  H. Goldschmidt,et al.  Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. , 2019, The New England journal of medicine.

[10]  Andre H Crepaldi,et al.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma , 2017, The New England journal of medicine.

[11]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[13]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Jessica Katz,et al.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.

[15]  J. Miguel,et al.  Defining and treating high-risk multiple myeloma , 2015, Leukemia.

[16]  R. Orlowski,et al.  Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211 , 2015, Blood Cancer Journal.

[17]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[18]  S. Jagannath,et al.  Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Pégourié,et al.  Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Jakubowiak,et al.  Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Barlogie,et al.  Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols , 2012, Leukemia.

[22]  John Crowley,et al.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. , 2011, Blood.

[23]  D. Hose,et al.  Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone , 2011, Cancer.

[24]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[25]  B. Barlogie,et al.  Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. , 2010, Blood.

[26]  N. Munshi,et al.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.

[27]  F. Zhan,et al.  CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008, Clinical Cancer Research.

[28]  B. Barlogie,et al.  Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 , 2007, British journal of haematology.

[29]  Emilie Flaberg,et al.  Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells , 2007, Molecular Cancer Therapeutics.

[30]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[31]  Jeroen Kuipers,et al.  The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint , 2004, British journal of haematology.

[32]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[33]  Terry L. Smith,et al.  High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. , 1991, Annals of internal medicine.

[34]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.